Edelstein, Charles PhD
Professor at
University of Colorado Denver
Leading researcher
with 231 publications
in the last 38 years
ORCID:
0000-0002-1330-632X
Charles L. Edelstein, MD is Professor of Medicine in the Division of Nephrology and Hypertension at the University of Colorado. For more than 25 years, the Edelstein laboratory has performed translational research on autosomal dominant polycystic kidney disease (ADPKD) and acute kidney injury (AKI). ADPKD is the commonest hereditary kidney disorder. ADPKD leads to chronic kidney disease often requiring dialysis and kidney transplantation. Our ADPKD studies in rats and mice have focused on cell signaling pathways that cause the cells lining the kidney cysts to proliferate, undergo cell death (apoptosis) and undergo mechanisms of cell survival (autophagy) resulting in growth of the cysts. We were the first to describe the activation of caspase-3, the major mediator of apoptosis, in PKD. To determine the role of apoptosis in PKD, we inhibited caspase-3 in rodent models of PKD and found that both genetic and pharmacological methods of caspase and apoptosis inhibition decreased tubular cell proliferation, slowed PKD and improved kidney function. These studies demonstrated the crucial and deleterious role of caspase-3-mediated apoptosis in PKD. As the mammalian target of rapamycin (mTOR) pathway plays an important role in apoptosis, we studied mTOR signaling in PKD. We demonstrated that mTOR inhibition with rapamycin, mTOR kinase inhibitors or an mTOR antisense oligonucleotide (ASO) slows the progression of PKD and improves kidney function in experimental models of PKD. mTOR signaling and apoptosis is integrally linked with a process called autophagy, that helps cells to survive various insults. We published the first report of decreased autophagy in polycystic kidneys. We have developed novel techniques to determine autophagic flux both in vivo in the kidney and in vitro in tubular cells. Cardiac disease is a common cause of death in patients with ADPKD. We have described for the first time that there is activation of AMPK, increased mTORC1/2, suppressed autophagy and cardiac hypertrophy in hearts from PKD mice. Our current studies focus on novel mTOR signaling pathways in both the kidneys and heart in experimental PKD models. AKI is a common acute kidney disorder that results mainly from systemic sepsis and shock and has a high mortality in patients in the intensive care unit. In 1995 we described the role of the cysteine protease, calpain, in AKI. In the late 1990s a group of cysteine proteases called caspases, that mediated programmed cell death or apoptosis, were discovered. We focused on caspase-1, also known as Interleukin-1 converting enzyme or ICE, that activates the cytokines IL-1 and IL-18. In two papers in J. Clin. Invest. in 2001 and 2002, we described that IL-18 was both a mediator and biomarker of AKI and that the injurious effect of IL-18 in AKI was independent of neutrophils. Recently, we discovered that IL-33, another IL-1 family cytokine that is activated by caspases, is a mediator of cisplatin-induced AKI. Our mouse studies in 2001 that IL-18 increases in the kidney and urine in AKI were the first suggestion of the use of biomarkers that come from the kidney to diagnose AKI rather than serum creatinine that has been used since 1917. The IL-18 work was taken to the bedside and we received a patent in 2006 for IL-18 as a biomarker of AKI in humans. We demonstrated that IL-18 is an early biomarker of AKI that increases before serum creatinine in patients with delayed graft function and patients post cardiac surgery. In summary, our laboratory has made original discoveries on the role of the cysteine proteases and cysteine protease-derived cytokines in both PKD and AKI. Both our IL-18 biomarker studies in AKI and our mTOR studies in rodents with PKD have been translated to the bedside.
show More
Preview
Evolution over the last 10 years of activity
Aggregated career metrics
231
Total documents
6.5
Normalized Impact
72
Highly Cited Papers (10%)
22.51
International Collab. (%)
Most cited publications
Main coauthors
Following you can review Charles's accomplishments in each of the dimensions.
The perfect present for a young Researcher!
Let's do it!
Dimensions One by One
Spanning 73 diverse indicators, the dimensions considered capture a comprehensive spectrum of academic
attributes.
Each dimension includes a set of indicators and has a especific weight on the One Index.
More information here...
Activity
757
/1000
Reflects an author's research output.
Impact
957
/1000
Reflects an author's academic visibility and the exceptional quality and influence of their most highly cited works.
Excellence
965
/1000
Reflects an author's academic visibility and the exceptional quality and influence of their most highly cited works.
Leadership
892
/1000
Reflects an author's efforts and commitment in leading research initiatives.
Cooperation
785
/1000
Reflects a researcher's ability to navigate and thrive in varied academic and research environments, highlighting adaptability, resourcefulness, and the capacity to build and maintain collaborative relationships across the spectrum of their career.
Openness
931
/1000
Reflects an author's commitment to making their research freely accessible and open to the public.
Community Support
509
/1000
Reflects an author's contributions to the academic community beyond their own research.
Community Recognition
0
/1000
Reflects the academic community's acknowledgment and appreciation of an author's contributions.
Transference
0
/1000
Reflects an author's commitment to making their research a practical application and real-world impact of an author's research.
Fundraising
0
/1000
Reflects an author's ability in securing project funding from major global entities, showcasing your ability to drive research initiatives forward.
All indicators
Performance
Activity
Reflects an author's research output.
| Documents | 231 | Count of all document types. |
|---|---|---|
| Docs/Year | 6.08 | Average of documents published by author per year. |
| Citable docs | 212 | Count of journal articles, proceeding papers and reviews. |
| Journal Articles | 182 | Documents published as articles in scientific journals usually peer-reviewed. |
| Conferences | 0 | Original article reporting data presented at a conference or symposium. |
| Reviews | 30 | Review papers authored by the researcher. |
| Patents | 0 | Intellectual property that gives its owner the legal right to exclude others from making, using, or selling an invention for a limited period of time in exchange for publishing an enabling disclosure of the invention. |
| Theses | 0 | Document submitted in support of candidature for an academic degree or professional qualification presenting the author's research and findings |
| Books | 1 | A whole monograph or the entire book. |
| Book Chapters | 0 | Complete chapter in a book or book series volume where the item is identified as a chapter by a heading or section indicator. |
| Datasets | 2 | Number of dataset where the author have contributed to the creation. |
| Editorials | 1 | Papers where the author contributed editorial content. |
| Reports | 0 | Research reports or white papers authored. |
| Grants | 0 | Research projects funded through external grants awarded to the author. |
| Pre-Prints | 1 | Number of publications freely available in pre-print format. |
| Clinical Trials | N/A | Number of clinical trials where the author has participated. |
| Other types | 0 | Other type of documents. |
Impact
Reflects an author's academic visibility and the exceptional quality and influence of their most highly cited works.
| Citations | 27497 | Total number of citations to all the publications attributed to the author (all types). |
|---|---|---|
| Self Citations | 735 | Citations where the author references their own previous work. |
| Self Citation Rate | 2.673 | Percentage of self-citations in the author's total citation count. |
| Non Self Citation Rate | 97.327 | Percentage of citations received from sources that are not self-citations. |
| Hot Citations | 679 | Total number of citations recieved in the last 6 months. |
| Citations/Document | 119.03 | Average of citations recieved per document. |
| % Not Cited | 0.0 | Percentage of documents with no citations recieved. |
| Relative Citation Index | 6.503 | Item oriented indicator consisting of the quotient between the number of citations to a given work and the average number of citations to works of the same type, year and discipline. An author's RCI corresponds to the average of the values of his/her publications. |
| Journal Relative Citation Index | 2.899 | Item oriented indicator consisting of the quotient between the number of citations to a given work and the average number of citations to works of the same type, year and journal. An author's RCI corresponds to the average of the values of his/her publications. |
| H Index | 71 | Maximum value of h such that the given author has published at least h papers that have each been cited at least h times. |
| G Index | 165 | Maximum value of g such that the given author has published at least g papers that have each been cited at least g^2 times. |
| i10 Index | 154 | Number of documents with at least 10 citations recieved. |
Excellence
Reflects an author's academic visibility and the exceptional quality and influence of their most highly cited works.
| Citation Score | 0.666 | Ratio between 0 and 1 being 0 corresponding to the citation percentile being 0 the 0th and 1 the 100th. |
|---|---|---|
| Citation Normalized Percentile | 0.668 | Citation percentile normalized to 1 (0 worst, 1 best) of the position in citations rankin within the field. Provided by OpenAlex. |
| Higly Cited Papers (top 10%) | 72 | Count of publications falling on or above the 90th citation percentile in the cohort of publications of the same type, year and discipline. |
| Relative Higly Cited Papers | 3.117 | Quotient between the real number of Highly Cited Papers (HCP) and expected number of HCP's that is the 10% of total documents. |
| Outstanding Papers (top 1%) | 14 | Count of publications falling on or above the 99th citation percentile in the cohort of publications of the same type, year and discipline. |
| Relative Outstanding Papers | 6.061 | Quotient between the real number of Outstanding Papers (OP) and expected number of OP's that is the 1% of total documents. |
| Outstanding Papers (top 0.1%) | 3 | Count of publications falling on or above the 99.9th citation percentile in the cohort of publications of the same type, year and discipline. |
| Hot Papers | 13 | Using only the citations recieved in the last 6 months: documents falling on or above the 99th citation percentile in the cohort of publications of the same type, year and discipline. |
Interaction within community
Leadership
Reflects an author's efforts and commitment in leading research initiatives.
| Docs Leadership | 145 | Number of documents lead by the author. |
|---|---|---|
| % Leadership | 62.77 | Percentage of documents lead by the author. |
| Docs International Leadership | 20 | Number of documents in international collaboration lead by the author. |
| % International Leadership | 8.66 | Percentage of documents in international collaboration lead by the author. |
| Principal Investigator | 0 | Number of times where the author served as the lead researcher in a project. |
| Associations Founded | 0 | Number of associations founded by the author. |
| Societies Founded | 0 | Number of scientific or professional societies established by the author. |
| Foundations Founded | 0 | Number of research-related foundations established by the author. |
| Councils | 0 | Number of councils founded by author. |
Cooperation
Reflects a researcher's ability to navigate and thrive in varied academic and research environments, highlighting adaptability, resourcefulness, and the capacity to build and maintain collaborative relationships across the spectrum of their career.
| Authors/Paper | 62.79 | Average number of authors per document. |
|---|---|---|
| % Highly Authored Papers | 3.46 | Percentage of documents with 25 or more authors. |
| Countries/Paper | 1.63 | Average number of different countries in the author's affiliation line per document. |
| Docs International Collaboration | 52 | Number of documents reporting two or more different countries in the author's affiliation line. |
| % International Collaboration | 22.51 | Percentage of documents reporting two or more diffetent countries in the author's affiliation line. |
Community Support
Reflects an author's contributions to the academic community beyond their own research.
| Peer Review Counts | 4 | Number of times the author peer-reviewed publications. |
|---|---|---|
| Society Membership | 0 | Number of societies of wich the author is a member. |
| Society Memberships | 0 | Memberships held by the author in scientific or professional societies. |
| Editorial Board Memberships | 0 | Number of journals where the author has been member of editorial board. |
| Panelists | 0 | Number of times the author have been a panelist in the European Research Council (ERC) calls. |
Community Recognition
Reflects the academic community's acknowledgment and appreciation of an author's contributions.
| Distinctions | 0 | Number of times the author have recieved a distinction for its career. |
|---|---|---|
| Invitations | 0 | Number of times the author has been invited to talks, professorships, expositions or demonstrations. |
| Talks | 0 | Number of times the author has been invited to talks. |
| Professorships | 0 | Number of times the author has been invited to professorhips. |
| Commissioned Reports | 0 | Commissioned reports done by the author. |
Interaction with society
Openness
Reflects an author's commitment to making their research freely accessible and open to the public.
| Open Access Documents | 137 | Number of documents in Open Access mode. |
|---|---|---|
| % Open Access Documents | 59.31 | Percentage of documents in Open Access mode. |
| Open Access Gold | 18 | Number of documents published in an OA journal that is indexed by the DOAJ. |
| Open Access Green | 30 | Toll-access on the publisher landing page, but there is a free copy in an OA repository. |
| Open Access Hybrid | 7 | Free under an open license in a toll-access journal. |
| Open Access Bronze | 80 | Free to read on the publisher landing page, but without any identifiable license. |
| Open Access Closed | 94 | Non Open Access documents. |
Transference
Reflects an author's commitment to making their research a practical application and real-world impact of an author's research.
| Patents | 0 | Intellectual property that gives its owner the legal right to exclude others from making, using, or selling an invention for a limited period of time in exchange for publishing an enabling disclosure of the invention. |
|---|---|---|
| Advisory Boards | 0 | Number of advisory boards of which the author is member. |
| Companies | 0 | Number of companies created or founded by the author. |
Fundraising
Reflects an author's ability in securing project funding from major global entities, showcasing your ability to drive research initiatives forward.
| Funding Counts | 0 | Number of activities reported as funding recieved. |
|---|---|---|
| ERC Grantees | 0 | Researchers awarded grants from the European Research Council. |